Investor Relations - Talis Biomedical

Press Releases

17 Feb '21

Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the closing of its previously announced initial public offering of

11 Feb '21

Talis Announces Pricing of Initial Public Offering

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of

27 Jan '21

Talis Appoints Melissa L. Gilliam, M.D., M.P.H., to Board of Directors

Clinician and Academician Brings Expertise in Women's and Adolescents' Health and Focus on Diversity, Equity, and Inclusion MENLO PARK, Calif., Jan. 27, 2021 /PRNewswire/ -- Talis Biomedical Corporation , a company dedicated to developing innovative molecular diagnostic tests for infectious

12 Nov '20

Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

Rob Kelley Named Chief Commercial Officer, Bringing to Talis Nearly 25 Years of Commercial and Sales Experience with a Focus in Diagnostics Douglas Liu Named Senior Vice President, Operations, Bringing to Talis 35 Years of Experience Leading Operations, Strategic Planning and R&D in Molecular

Excellence at the Point of Care

Corporate Profile

Stock Information

Press Releases

Recent Events

Brian Coe

Chief Executive Officer, Co-Founder

Karen E. Flick, J.D., Ph.D.

Chief of Staff and Senior Vice President, Legal

Roger Moody

Chief Financial Officer

Rob Kelley

Chief Commercial Officer